ReShape is More Than Just ‘The Lap-Band company’Bariatric News caught up with Bart Bandy, CEO of ReShape LifeSciences™, to discuss the latest developments at the company including the...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events2 days ago